Is addition of PD-1/PD-L1 inhibitor to platinum-based chemotherapy recommended in patients with PS 0–2, when their tumor is driver oncogene-negative and PD-L1 is < 50%, or unknown? The gene discussed is CD274; the disease is neoplasm.